pharmaphorum Top Stories 19 August 2024
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
Welcome to our weekly round-up of the top stories from healthcare, pharma, biotech and digital health.
The US Inflation Reduction Act's drug pricing negotiation provisions have been the talk of the industry for two years, but this week we finally got some substance - the negotiated prices for the first 10 drugs. And it's likely no coincidence that those prices are coming out so close to the US election in November. Aside from that, we have an unexpected FDA snub for a closely watched MDMA drug, an unexpected NIH snub for the only mPox drug, and two bits of news for 阿斯利康 - one good, one not so good. Check out this week's top stories below and head to pharmaphorum.com for more industry updates.
Top Stories
Biden, Harris 'just getting started' on IRA drug price cuts
In their first joint appearance since Joe Biden withdrew from the Presidential race to be replaced on the Democrat ticket by Kamala Harris , the duo celebrated the long sought-after Medicare drug price reductions – and reaffirmed their commitment. READ MORE
As WHO calls mpox emergency, NIH says only drug ineffective
The only antiviral recognised as an mpox treatment was unable to shorten the time to resolution of lesions in a trial in the Democratic Republic of the Congo (DRC), the epicentre of an outbreak deemed a public health emergency by the World Health Organization yesterday. READ MORE
AstraZeneca said to be wavering on ￡450m UK vaccine plant
阿斯利康 's plan to invest ￡450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times. READ MORE
FDA shoots down Lykos' MDMA therapy for PTSD
The FDA has denied Lykos Therapeutics ' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic medicines category. READ MORE
领英推荐
AZ gets landmark approval for Imfinzi/Lynparza combo
AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer. READ MORE
Beyond treatment: Addressing the holistic needs of cancer survivors
For patients, beating cancer is just the beginning. But how can healthcare professionals support the growing number of survivors as they navigate life post-remission? DISCOVER MORE
Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors. SIGN UP
MBBS Doctor from services institute of medical sciences
2 个月?? Stay Informed! ?? The 2024 Monkeypox outbreak is making headlines, and it's crucial to stay informed about this re-emerging viral threat. In our latest video, we break down everything you need to know about the Monkeypox virus, including its transmission, symptoms, and prevention measures. Whether you're concerned about the global spread or just want to be prepared, this comprehensive overview will give you the knowledge you need to protect yourself and your loved ones. ?? Watch the full video here: https://youtu.be/dzn5bP5LV04 ?? Don't forget to subscribe to our channel for more updates on global health issues and medical insights. Stay safe and informed, Fellow Medics! #Monkeypox2024 #PublicHealth #ViralOutbreak #StayInformed #HealthAwareness #FellowMedics This should help you effectively engage your audience and provide valuable information on the Monkeypox outbreak!